MERIAL, Now Part of BOEHRINGER INGELHEIM, Grows Canine Vaccine Portfolio With Introduction of RECOMBITEK® Oral Bordetella
RECOMBITEK Oral Bordetella is administered in the dog’s buccal cavity (inside the cheek). Clinical studies suggest that as a mucosal vaccine, it offers dogs a robust immune response after a single dose. 1
“Because of the disease’s common name, “kennel cough,” people may think it’s a disease only kenneled animals can get,” said Frank Capella, DVM of Village Veterinary Hospital in Canastota, NY. “But it causes a highly contagious disease spread through social contact. Many dogs are at risk. Vaccination by a veterinarian remains the first line of defense.”
B. bronchiseptica stands out as one of the primary pathogens responsible for canine infectious respiratory disease complex, a serious condition whose signs include coughing, sneezing, nasal and/or ocular discharge, lethargy and loss of appetite. In severe cases, signs can progress to lower respiratory disease, such as pneumonia, and even death. B. bronchiseptica is unique in its ability to evade the immune system for weeks to months. During this time, a dog that appears clinically normal could be exposing other dogs.
“Merial, now a part of Boehringer Ingelheim, is pleased to expand its portfolio with an oral Bordetella vaccine,” said Zach Mills, DVM, executive director of Boehringer Ingelheim’s U.S. Pet Vet Veterinary Professional Services. “For many dogs, oral delivery may mean a less stressful experience without the unpleasant sneeze backs of alternative vaccines delivered through the nose. The packaging’s flip-top vial cap allows for easy opening by veterinary staff, and the safe, needle-free pipette simplifies the vaccination process while reducing risk of injury.”
RECOMBITEK vaccines are proven and backed up by the Pet Vaccines Customer Satisfaction Guarantee.
RECOMBITEK vaccines are manufactured by Merial. Merial is now a part of Boehringer Ingelheim.
References
1 Data on file.